Baseline characteristics of studies, including BCS patients
| Reference . | Y . | Design . | Male/female . | Median age, y (range) . | Median follow-up, mo (range) . | MPN criteria . | MPN . | JAK2V617F . | Classification (PV/ET/MF/U/solitaryJAK2)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||||||||
| Smira et al58 | 2010 | RC | NA | NA | NA | NA | NA | NA | 14/20 | 70 | NA |
| Zahn et al61 | 2010 | RC | 4/16 | 34 (14-60)† | NA | BM if MPN was suspected | 6/20 | 30 | NA | NA | 4/1/0/1/0 |
| Darwish Murad et al4 | 2009 | RC | 70/93 | 38 (16-83) | 17 (0.1-31) | WHO 2001, BM in majority of patients | 56/103 | 39 | 35/121 | 29 | 27/9/2/15/3 |
| Xavier et al60 | 2009 | RC | 11/20 | 33 (17-50) | 51 (1-104) | WHO 2001, BM if MPN was suspected | 8/31 | 26 | 8/31 | 26 | 4/2/0/0/2 |
| Rajani et al8 | 2009 | RC | 19/24 | 40 (4-80) | 32 (0.5-192) | BM in 79% of patients | 14/36 | 39 | NA | NA | 8/6/0/0 |
| Kiladjian et al20 | 2008 | RC | 69/35 | 36 (IQR 27-46) | 47 (range NA) | BM in nearly all patients | 47/104 | 45 | 47/104 | 45 | 17/3/0/27/0 |
| Colaizzo et al53 | 2008 | RC | 9/23 | 35 (14-66) | NA | WHO criteria 2001 | 17/32 | 53 | 11/32 | 34 | 4/1/9/2/1 |
| Uskudar et al59 | 2008 | RC | 40/35 | 34 (14-72)† | 18 (1-30) | BM if MPN was suspected | 6/72 | 8 | NA | NA | 5/1/0/0/0 |
| DeStefano et al63 | 2007 | RC | 4/11 | NA | 48 (24-108)‡ | PVSG 2000 | 5/15 | 33 | 5/15 | 33 | 1/3/0/0/1 |
| Smalberg et al9 | 2006 | RC | 14/26 | 28 (18-53) | 7.1 ± 6.9† | WHO 2001, BM in majority of patients | 13/40 | 33 | 7/17 | 41 | 6/6/0/1/0 |
| Patel et al51 | 2006 | RC | 15/26 | 36 ± 13.3 | 49 (8-87)§ | BM in all patients | 27/55 | 49 | 24/41 | 59 | 6/8/0/14/0 |
| Primignani et al52 | 2006 | RC | 8/12 | 33 (19-72) | NA | WHO 2001, based on BM only | 9/20 | 45 | 8/20 | 40 | 3/3/0/3/0 |
| Eapen et al62 | 2006 | RC | 22/39 | 36 (16-77) | 52 (0-181) | Not specified | 17/61 | 28 | NA | NA | 7/6/1/3/0 |
| Khuroo et al54 | 2005 | RC | 17/23 | 27 ± 7.3† | NA | BM if MPN was suspected | 4/40 | 10 | NA | NA | 1/3/0/0/0 |
| Darwish Murad et al5 | 2004 | RC | 78/159 | 35 (13-76) | 44 (0-203) | BM if MPN was suspected | 54/237 | 23 | NA | NA | 45/9/0/0/0 |
| Attwell et al74 | 2004 | RC | 7/15 | 24 (18-68)† | NA | BM if MPN was suspected | 11/22 | 50 | NA | NA | 8/3/0/0/0 |
| Janssen et al47 | 2000 | CC | 16/27 | 40 (19-60) | NA | BM if MPN was suspected | 12/43 | 28 | NA | NA | 10/1/0/1/0 |
| Denninger et al6 | 2000 | RC | NA | NA | NA | BM if MPN was suspected | 12/32 | 38 | NA | NA | 12/0/0/4/0 |
| Mahmoud et al7 | 1996 | RC | 17/27 | 37 (19-60)† | NA | BM if MPN was suspected | 17/42 | 40 | NA | NA | 11/5/1/0/0 |
| Reference . | Y . | Design . | Male/female . | Median age, y (range) . | Median follow-up, mo (range) . | MPN criteria . | MPN . | JAK2V617F . | Classification (PV/ET/MF/U/solitaryJAK2)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||||||||
| Smira et al58 | 2010 | RC | NA | NA | NA | NA | NA | NA | 14/20 | 70 | NA |
| Zahn et al61 | 2010 | RC | 4/16 | 34 (14-60)† | NA | BM if MPN was suspected | 6/20 | 30 | NA | NA | 4/1/0/1/0 |
| Darwish Murad et al4 | 2009 | RC | 70/93 | 38 (16-83) | 17 (0.1-31) | WHO 2001, BM in majority of patients | 56/103 | 39 | 35/121 | 29 | 27/9/2/15/3 |
| Xavier et al60 | 2009 | RC | 11/20 | 33 (17-50) | 51 (1-104) | WHO 2001, BM if MPN was suspected | 8/31 | 26 | 8/31 | 26 | 4/2/0/0/2 |
| Rajani et al8 | 2009 | RC | 19/24 | 40 (4-80) | 32 (0.5-192) | BM in 79% of patients | 14/36 | 39 | NA | NA | 8/6/0/0 |
| Kiladjian et al20 | 2008 | RC | 69/35 | 36 (IQR 27-46) | 47 (range NA) | BM in nearly all patients | 47/104 | 45 | 47/104 | 45 | 17/3/0/27/0 |
| Colaizzo et al53 | 2008 | RC | 9/23 | 35 (14-66) | NA | WHO criteria 2001 | 17/32 | 53 | 11/32 | 34 | 4/1/9/2/1 |
| Uskudar et al59 | 2008 | RC | 40/35 | 34 (14-72)† | 18 (1-30) | BM if MPN was suspected | 6/72 | 8 | NA | NA | 5/1/0/0/0 |
| DeStefano et al63 | 2007 | RC | 4/11 | NA | 48 (24-108)‡ | PVSG 2000 | 5/15 | 33 | 5/15 | 33 | 1/3/0/0/1 |
| Smalberg et al9 | 2006 | RC | 14/26 | 28 (18-53) | 7.1 ± 6.9† | WHO 2001, BM in majority of patients | 13/40 | 33 | 7/17 | 41 | 6/6/0/1/0 |
| Patel et al51 | 2006 | RC | 15/26 | 36 ± 13.3 | 49 (8-87)§ | BM in all patients | 27/55 | 49 | 24/41 | 59 | 6/8/0/14/0 |
| Primignani et al52 | 2006 | RC | 8/12 | 33 (19-72) | NA | WHO 2001, based on BM only | 9/20 | 45 | 8/20 | 40 | 3/3/0/3/0 |
| Eapen et al62 | 2006 | RC | 22/39 | 36 (16-77) | 52 (0-181) | Not specified | 17/61 | 28 | NA | NA | 7/6/1/3/0 |
| Khuroo et al54 | 2005 | RC | 17/23 | 27 ± 7.3† | NA | BM if MPN was suspected | 4/40 | 10 | NA | NA | 1/3/0/0/0 |
| Darwish Murad et al5 | 2004 | RC | 78/159 | 35 (13-76) | 44 (0-203) | BM if MPN was suspected | 54/237 | 23 | NA | NA | 45/9/0/0/0 |
| Attwell et al74 | 2004 | RC | 7/15 | 24 (18-68)† | NA | BM if MPN was suspected | 11/22 | 50 | NA | NA | 8/3/0/0/0 |
| Janssen et al47 | 2000 | CC | 16/27 | 40 (19-60) | NA | BM if MPN was suspected | 12/43 | 28 | NA | NA | 10/1/0/1/0 |
| Denninger et al6 | 2000 | RC | NA | NA | NA | BM if MPN was suspected | 12/32 | 38 | NA | NA | 12/0/0/4/0 |
| Mahmoud et al7 | 1996 | RC | 17/27 | 37 (19-60)† | NA | BM if MPN was suspected | 17/42 | 40 | NA | NA | 11/5/1/0/0 |
RC indicates retrospective cohort; CC, case-control; U, unclassifiable; solitaryJAK2, solitary JAK2-positive; NA, not available; IQR, interquartile range; and BM, bone marrow biopsy.
MPNs that became overt during follow-up were included in subtype analysis.
Mean age/follow-up (range) or ± SD.
Median follow-up of patients with JAK2V617F-positive MPNs without elevated blood counts.
Median time of diagnosis to overt MPNs.